ITF Therapeutics
ITF Therapeutics is seeking a Neuromuscular Key Account Manager to drive the successful launch of a Duchenne muscular dystrophy treatment across a large territory. The role involves strategic account management, building relationships with prescribers, and leading sales initiatives to meet targets. The position requires collaboration with cross-functional teams and adherence to compliance policies.
Headquarters
Concord, Massachusetts, United States
Company Size
1-10 employees
Founded
2024
ITF Therapeutics LLC is the United States affiliate of Italfarmaco S.p.A., founded in 2024 and based in Concord, MA. The company focuses on bringing therapeutic options to people living with rare diseases, most notably commercializing DUVYZAT (givinostat), an FDA‑approved HDAC inhibitor for Duchenne muscular dystrophy (DMD), in the U.S. market. ITF combines a flexible, entrepreneurial approach with the resources and legacy of its parent organization to deliver treatments, support programs, and educational resources for patients, clinicians, and researchers.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for ITF Therapeutics.
101% above the average for this role
Neuromuscular Key Account Manager - Central Region
IQVIA
Rare Disease Account Manager- North Central Region
IQVIA
Rare Disease Account Manager- Atlantic Region
IQVIA
Rare Disease Account Manager- Pacific Region
IQVIA
Rare Disease Account Manager- Gulf Coast Region
IQVIA
VP, DM1 Commercial Asset Lead
Dyne Therapeutics